» Articles » PMID: 32898326

Genetic Modifiers of Long-term Survival in Sickle Cell Anemia

Overview
Journal Clin Transl Med
Publisher Wiley
Specialty General Medicine
Date 2020 Sep 8
PMID 32898326
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Sickle cell anemia (SCA) is a clinically heterogeneous, monogenic disorder. Medical care has less-than-optimal impact on clinical outcomes in SCA in Africa due to several factors, including patient accessibility, poor access to resources, and non-availability of specific effective interventions for SCA.

Methods: Against this background, we investigated 192 African participants who underwent whole exome sequencing. Participants included 105 SCA patients spanning variable clinical expression: a "long survivor" group (age over 40 years), a "stroke" group (at least one episode of overt stroke), and a "random" group (patients younger than 40 years without overt cerebrovascular disease). Fifty-eight ethnically matched homozygous hemoglobin A controls were also studied. Findings were validated in an independently recruited sample of 29 SCA patients. Statistical significance of the mutational burden of deleterious and loss-of-function variants per gene against a null model was estimated for each group, and gene-set association tests were conducted to test differences between groups.

Results: In the "long survivor" group, deleterious/loss-of-function variants were enriched in genes including CLCN6 (a voltage-dependent chloride channel for which rare deleterious variants have been associated with lower blood pressure) and OGHDL (important in arginine metabolism, which is a therapeutic target in SCA). In the "stroke" group, significant genes implicated were associated with increased activity of the blood coagulation cascade and increased complement activation, for example, SERPINC1, which encodes antithrombin. Oxidative stress and glutamate biosynthesis pathways were enriched in "long survivors" group. Published transcriptomic evidence provides functional support for the role of the identified pathways.

Conclusions: This study provides new gene sets that contribute to variability in clinical expression of SCA. Identified genes and pathways suggest new avenues for other interventions.

Citing Articles

FLT1 and other candidate fetal haemoglobin modifying loci in sickle cell disease in African ancestries.

Wonkam A, Esoh K, Levine R, Ngo Bitoungui V, Mnika K, Nimmagadda N Nat Commun. 2025; 16(1):2092.

PMID: 40025045 PMC: 11873275. DOI: 10.1038/s41467-025-57413-5.


Genetic Modifiers of Sickle Cell Anemia Phenotype in a Cohort of Angolan Children.

Ginete C, Delgadinho M, Santos B, Miranda A, Silva C, Guerreiro P Genes (Basel). 2024; 15(4).

PMID: 38674403 PMC: 11049512. DOI: 10.3390/genes15040469.


The dawn of a cure for sickle cell disease through CRISPR-based treatment: A critical test of equity in public health genomics.

Mboowa G, Sserwadda I, Kanyerezi S, Tukwasibwe S, Kidenya B Ann Hum Genet. 2024; .

PMID: 38517013 PMC: 11416560. DOI: 10.1111/ahg.12558.


Whole genome sequencing reveals population diversity and variation in HIV-1 specific host genes.

Thami P, Choga W, Dandara C, OBrien S, Essex M, Gaseitsiwe S Front Genet. 2024; 14:1290624.

PMID: 38179408 PMC: 10765519. DOI: 10.3389/fgene.2023.1290624.


A new era dawns on sickle cell disease in India.

Kishore R, Gupta M, Gupta K Indian J Med Res. 2023; 157(6):491-493.

PMID: 37530303 PMC: 10466490. DOI: 10.4103/ijmr.ijmr_1045_23.


References
1.
Setty B, Stuart M, Dampier C, Brodecki D, Allen J . Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. Lancet. 2003; 362(9394):1450-5. DOI: 10.1016/S0140-6736(03)14689-2. View

2.
Kija E, Saunders D, Munubhi E, Darekar A, Barker S, Cox T . Transcranial Doppler and Magnetic Resonance in Tanzanian Children With Sickle Cell Disease. Stroke. 2019; 50(7):1719-1726. PMC: 6594727. DOI: 10.1161/STROKEAHA.118.018920. View

3.
Rumaney M, Ngo Bitoungui V, Vorster A, Ramesar R, Kengne A, Ngogang J . The co-inheritance of alpha-thalassemia and sickle cell anemia is associated with better hematological indices and lower consultations rate in Cameroonian patients and could improve their survival. PLoS One. 2014; 9(6):e100516. PMC: 4076272. DOI: 10.1371/journal.pone.0100516. View

4.
McGann P, Hernandez A, Ware R . Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research. Blood. 2016; 129(2):155-161. PMC: 5234214. DOI: 10.1182/blood-2016-09-702324. View

5.
Hamideh D, Alvarez O . Sickle cell disease related mortality in the United States (1999-2009). Pediatr Blood Cancer. 2013; 60(9):1482-6. DOI: 10.1002/pbc.24557. View